Trial
NCT04064697
Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Ministry of Health, France
Condition
Ulcerative Colitis, Unspecified
Intervention
Valganciclovir
Why stopped
low of inclusions
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-10